BioLineRx (NASDAQ: BLRX) CFO reports extensive stock option grants and shares
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
BioLineRx Ltd. chief financial officer Zeevi Mali filed an initial ownership report listing his equity position in the company. The filing shows multiple employee stock option grants over several years under the 2003 Amended and Restated Share Incentive Plan, alongside direct holdings of 1,311,000 Ordinary Shares.
The disclosed options cover underlying Ordinary Shares at exercise prices ranging from $0.0060 to $0.2870, with expiration dates between 2026 and 2035. Earlier grants from 2016 through 2022 are fully vested, while a grant dated March 21, 2023 is partly vested and continues to vest quarterly, and a large grant dated November 19, 2025 had no vested options initially and will vest over a one-year cliff and then 12 quarterly installments, subject to continued service. Certain securities tied to the plan are required to be registered in the name of a trustee to qualify for Israeli tax benefits.
Positive
- None.
Negative
- None.
Insider Trade Summary
9 transactions reported
Mixed
9 txns
Insider
Zeevi Mali
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Employee Stock Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares, 0.1 NIS per share | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 43,800 shares (Direct);
Ordinary Shares, 0.1 NIS per share — 1,311,000 shares (Direct)
Footnotes (1)
- Options granted under the 2003 Amended and Restated Share Incentive Plan. The grant date of this grant is October 9, 2016. This option grant is fully vested as of this date. The grant date of this grant is February 21, 2017. This option grant is fully vested as of this date. The grant date of this grant is December 26, 2017. This option grant is fully vested as of this date. The grant date of this grant is March 25, 2019. This option grant is fully vested as of this date. The grant date of this grant is November 17, 2020. This option grant is fully vested as of this date. The grant date of this grant is March 15, 2022. This option grant is fully vested as of this date. The grant date of this grant is March 21, 2023. As of this date, 741,600 of the options were vested as of the date of appointment. The remaining 337,200 options will vest in 5 equal quarterly installments, subt to the Reporting Person's continued service to the Issuer as of each vesting date. The grant date of this grant is November 19, 2025. As of this date, none of the options were vested. As of the grant date 3,420,000 options have a one-year cliff and the remaining 10,260,000 options will vest in 12 equal quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee.
FAQ
What does BioLineRx (BLRX) CFO Zeevi Mali report in this Form 3?
Zeevi Mali reports his initial ownership in BioLineRx, including multiple employee stock option grants and 1,311,000 Ordinary Shares. The options span several grant years, exercise prices, and expiration dates, outlining his long-term equity-based compensation and potential future share ownership.
What stock option grants are disclosed for the BioLineRx (BLRX) CFO?
The CFO discloses several employee stock option grants under the 2003 Amended and Restated Share Incentive Plan, with exercise prices from $0.0060 to $0.2870 and expiration dates between 2026 and 2035, each covering a specified number of underlying Ordinary Shares.
Which BioLineRx CFO option grants are already fully vested?
Option grants with grant dates of October 9, 2016, February 21, 2017, December 26, 2017, March 25, 2019, November 17, 2020, and March 15, 2022 are described as fully vested, meaning all related options are currently exercisable under their respective terms.
How do the March 2023 and November 2025 BioLineRx option grants vest for the CFO?
The March 21, 2023 grant has 741,600 options vested at appointment, with 337,200 vesting in five equal quarterly installments. The November 19, 2025 grant has a one-year cliff on 3,420,000 options, while 10,260,000 vest in 12 equal quarterly installments, conditional on continued service.
Why are some BioLineRx CFO plan securities registered in a trustee’s name?
To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee under the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee, rather than directly in the employee’s name.